Uguagliati, Beatrice
(2020)
Prenatal treatment with the flavonoid 7,8-DHF improves trisomy-linked proliferation defects in numerous brain regions of the Ts65Dn model of Down syndrome, [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Scienze biomediche e neuromotorie, 33 Ciclo. DOI 10.6092/unibo/amsdottorato/9537.
Documenti full-text disponibili:
|
Documento PDF (English)
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (7MB)
|
Abstract
Intellectual disability (ID) is the unavoidable hallmark and the most invalidating feature of DS, a genetic pathology due to triplication of chromosome 21. ID in DS is mainly due to neurodevelopmental alterations among which neurogenesis reduction appears to play a prominent role. Considering the time course of brain development and that the bulk of neurogenesis takes place prenatally, therapeutic interventions aimed at correcting brain developmental defects should be started prenatally. 7,8-DHF is a natural flavonoid that crosses the blood brain barrier, and specifically binds the TrkB receptor activating its downstream signaling cascade. We previously found that neonatal treatment with 7,8-DHF improves cellularity and restores dendritic pathology in the hippocampus of the Ts65Dn mouse, the most studied DS mouse model that largely mimics the human condition. Based on these premises the goal of the current study was to establish whether prenatal treatment with 7,8-DHF is able to rescue overall brain neurogenesis. Ts65Dn pregnant females received 7,8-DHF from embryonic day 10 until delivery. In 2-days-old pups, we evaluated the number of proliferating (BrdU+) cells in various forebrain neurogenic niches. Namely, the rostral and caudal subventricular zone, dentate gyrus, rostral and caudal neocortex, striatum, thalamus and hypothalamus. We found that in treated Ts65Dn mice the proliferation potency was improved or even restored in most of the examined regions. Moreover, treatment restored cellularity in the neocortex layer II but not in the hippocampus. These results show that 7,8-DHF has a positive influence on prenatal neurogenesis and cortical cellularity in the Ts65Dn mouse model, but, unlike neonatal treatment, it has moderate effects on hippocampal cellularity. A treatment with 7,8-DHF that starts embryonically and continues in the early postnatal period should be considered as a promising strategy for the improvement of overall brain development in DS.
Abstract
Intellectual disability (ID) is the unavoidable hallmark and the most invalidating feature of DS, a genetic pathology due to triplication of chromosome 21. ID in DS is mainly due to neurodevelopmental alterations among which neurogenesis reduction appears to play a prominent role. Considering the time course of brain development and that the bulk of neurogenesis takes place prenatally, therapeutic interventions aimed at correcting brain developmental defects should be started prenatally. 7,8-DHF is a natural flavonoid that crosses the blood brain barrier, and specifically binds the TrkB receptor activating its downstream signaling cascade. We previously found that neonatal treatment with 7,8-DHF improves cellularity and restores dendritic pathology in the hippocampus of the Ts65Dn mouse, the most studied DS mouse model that largely mimics the human condition. Based on these premises the goal of the current study was to establish whether prenatal treatment with 7,8-DHF is able to rescue overall brain neurogenesis. Ts65Dn pregnant females received 7,8-DHF from embryonic day 10 until delivery. In 2-days-old pups, we evaluated the number of proliferating (BrdU+) cells in various forebrain neurogenic niches. Namely, the rostral and caudal subventricular zone, dentate gyrus, rostral and caudal neocortex, striatum, thalamus and hypothalamus. We found that in treated Ts65Dn mice the proliferation potency was improved or even restored in most of the examined regions. Moreover, treatment restored cellularity in the neocortex layer II but not in the hippocampus. These results show that 7,8-DHF has a positive influence on prenatal neurogenesis and cortical cellularity in the Ts65Dn mouse model, but, unlike neonatal treatment, it has moderate effects on hippocampal cellularity. A treatment with 7,8-DHF that starts embryonically and continues in the early postnatal period should be considered as a promising strategy for the improvement of overall brain development in DS.
Tipologia del documento
Tesi di dottorato
Autore
Uguagliati, Beatrice
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
33
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Down syndrome; Ts65Dn; Prenatal neurogenesis; Flavonoids; Pharmacotherapy
URN:NBN
DOI
10.6092/unibo/amsdottorato/9537
Data di discussione
4 Dicembre 2020
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Uguagliati, Beatrice
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
33
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Down syndrome; Ts65Dn; Prenatal neurogenesis; Flavonoids; Pharmacotherapy
URN:NBN
DOI
10.6092/unibo/amsdottorato/9537
Data di discussione
4 Dicembre 2020
URI
Statistica sui download
Gestione del documento: